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Background: N-Myc Interactor is an inducible protein whose expression is compromised in advanced stage breast
cancer. Downregulation of NMI, a gatekeeper of epithelial phenotype, in breast tumors promotes mesenchymal, invasive
and metastatic phenotype of the cancer cells. Thus the mechanisms that regulate expression of NMI are of potential
interest for understanding the etiology of breast tumor progression and metastasis.
Method: Web based prediction algorithms were used to identify miRNAs that potentially target the NMI transcript.
Luciferase reporter assays and western blot analysis were used to confirm the ability of miR-29 to target NMI.
Quantitive-RT-PCRs were used to examine levels of miR29 and NMI from cell line and patient specimen derived RNA.
The functional impact of miR-29 on EMT phenotype was evaluated using transwell migration as well as monitoring 3D
matrigel growth morphology. Anti-miRs were used to examine effects of reducing miR-29 levels from cells. Western
blots were used to examine changes in GSK3β phosphorylation status. The impact on molecular attributes of EMT was
evaluated using immunocytochemistry, qRT-PCRs as well as Western blot analyses.
Results: Invasive, mesenchymal-like breast cancer cell lines showed increased levels of miR-29. Introduction of miR-29 into
breast cancer cells (with robust level of NMI) resulted in decreased NMI expression and increased invasion, whereas treatment
of cells with high miR-29 and low NMI levels with miR-29 antagonists increased NMI expression and decreased invasion.
Assessment of 2D and 3D growth morphologies revealed an EMT promoting effect of miR-29. Analysis of mRNA of NMI and
miR-29 from patient derived breast cancer tumors showed a strong, inverse relationship between the expression of NMI and
the miR-29. Our studies also revealed that in the absence of NMI, miR-29 expression is upregulated due to unrestricted Wnt/
β-catenin signaling resulting from inactivation of GSK3β.
Conclusion: Aberrant miR-29 expression may account for reduced NMI expression in breast tumors and mesenchymal
phenotype of cancer cells that promotes invasive growth. Reduction in NMI levels has a feed-forward impact on
miR-29 levels.
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N-myc interactor (NMI) is a cytokine (IL-2, IFNγ) indu-
cible protein that interacts with several transcription fac-
tors such as STATs, cMYC, BRCA1, TIP60 and SOX10, all
of which have known critical involvement in influencing
tumor progression and stem-ness [1-6]. Thus, a range of* Correspondence: rsamant@uab.edu
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unless otherwise stated.signaling activities have been associated with NMI. NMI
has been shown to augment STAT-mediated transcription
in response to cytokines, specifically by mediating associ-
ation of co-activator protein CBP/p300 with STAT1 or
STAT5 [3]. It has also been implicated in negative regula-
tion of cMyc driven hTERT transcription and positive
regulation of a subset of SOX10 regulated transcripts
[4,5]. NMI shows compartmentalized location, either cyto-
solic or nuclear. For example, in C6 glioma cells nuclear
NMI was more frequent in SOX10-expressing cells com-
pared to cells that lacked SOX10 [5]. These different loca-
tions may impact its function. In response to cellularLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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shown to translocate to the nucleus to stabilize ARF
(INK4a/ARF), a tumor suppressor, and aid in stabilization
of TP53 [7]. Disease relevance of NMI was highlighted in
our previous observations which revealed that NMI expres-
sion is negatively correlated with stage and grade of breast
tumors [8]. One of the mechanisms of NMI action in breast
cancer was implied in its ability to negatively modulate
transcriptional regulation of target genes by c-Myc. NMI fa-
cilitates formation of a tri-molecular complex that includes
BRCA1, NMI and c-Myc [4]. Our quest to understand the
details of functional relevance of NMI in cancer revealed
that restoring expression of NMI in tumorigenic and inva-
sive breast cancer and melanoma cell lines resulted in re-
duced growth of tumor xenografts in athymic mice [9].
Subsequent signaling studies revealed to us that NMI ex-
pression negatively regulates oncogenic Wnt/β-catenin sig-
naling [9]. We also observed that silencing NMI expression
from epithelial-like breast cancer cell lines induced molecu-
lar markers and morphological attributes of mesenchymal-
like phenotype as well as promoted the invasive ability of
these cells. Mechanistically, loss of NMI had negative
impacts on STAT5-driven expression of TGFβ signaling
repressor, SMAD7. This allowed for aberrant manifest-
ation of TGFβ-driven epithelial-mesenchymal-transition
(EMT) [8]. Based on this developing body of compel-
ling reports, it is apparent that loss of NMI expression
during tumor progression may prompt EMT and me-
tastases. Thus the mechanisms that negatively regulate
NMI expression are of potential interest to understand
the etiology of metastatic progression of breast tumors
and to identify potentially novel therapeutic targets.
While direct DNA mutations, translocation and dele-
tions account for altered gene expression in cancer,
epigenetic regulation, such as regulatory effects of
non-coding RNA, specifically miRNA, have been found to
be of equal importance in the development and propaga-
tion of many cancers [10-12]. MicroRNAs regulate gene
expression via transcriptional modification and/or inhib-
ition of translation [13,14]. While much is known about
specific mutations leading to an increased risk of develop-
ing breast cancer, similar roles for miRNAs are still being
progressively uncovered [15-17]. Here we report our in-
vestigations that report for the first time, that NMI is a
novel target of microRNA 29 (miR-29). Interestingly, we
also observe that absence of NMI prompts a feed forward
increase in miR-29 levels due to inactivation of GSK3β ac-
tivity. Cumulatively, our studies reveal a novel inverse
regulatory relationship of NMI and miR-29 in breast
cancer.
Materials and methods
All the methods were carried out in accordance with the
approved guidelines.Target prediction
The N-myc (and STAT) intereractor (NMI); gene ID:
9111, mature mRNA sequence (NM_004688.2) was
obtained from the NCBI and queried by the miRNA tar-
get prediction sites TargetScan(Human) [http://www.
targetscan.org/] [18,19] and microRNA.org [http://www.
microrna.org] (miRaNda algorithm) [20,21] and miRDB
[http://mirdb.org/miRDB] [22-24]. The predicted binding
strengths and scores were obtained. Only the miRNAs
common to at least 2 searches were considered for fur-
ther investigations.
Cell culture and reagents
Cells lines were obtained from the ATCC. MDA-MB-231
and MDA-MB-435 cells were grown in DMEM/F12 sup-
plemented with 5% heat inactivated fetal bovine serum.
MCF7 cells were grown in DMEM/F12 supplemented
with 10% heat inactivated fetal bovine serum and insulin
(10 μg/mL) (Sigma, St Louis, MO, USA). T47D cells were
grown in RPMI 1640 supplemented with sodium pyruvate
(1 μg/mL), 10% heat inactivated fetal bovine serum, and
insulin (10 μg/ml).
Antibodies
NMI mouse monoclonal (Sigma-9D8) (Sigma, St Louis,
MO, USA), GAPDH rabbit monoclonal (mAb#2118),
GSK-3β rabbit monoclonal (mAb#9315), E-cadherin
rabbit monoclonal (mAB#3195), Keratin 8/18 mouse
(mAb#4546) and phospho-GSK-3β-Ser9 rabbit monoclo-
nal mAb#9323 (Cell Signaling Technologies Inc., Boston,
MA, USA) were used.
Quantitative RT-PCR
Cells were grown to 70% confluence and total RNA was
harvested with TRIzol® reagent (Life Technologies,
Carlsbad, CA) or the SurePrep™TrueTotal™RNA purifi-
cation kit (Fisher Scientific, Pittsburgh, PA, USA). RNA
was quantitated and assessed using spectrophotometry
(NanoDrop Lite, Thermo Scientific, Wilmington, DE, USA)
for 260/280 and 260/230 ratio. Mature microRNA levels
were assessed with strand-specific reverse transcription
followed by quantitative PCR (Applied Biosystems, Foster
City, CA.
Total RNA was used to generate cDNA using primers
specific to RNU6B (control) or hsa-miR-29 a or b. PCR
was performed using both U6 (control) or hsa-miR-29a/
b Taqman primer probes and Taqman Universal Master
Mix, No Amperase UNG (Applied Biosystems). miR-29
miRNA levels were normalized to U6 levels.
To assess changes in mRNA, cDNA was generated
from 1 μg total RNA using the High Capacity Reverse
Transcription cDNA synthesis kit (Applied Biosystems,
Foster City, CA). Subsequently, PCR was done with
TaqMan primer probes specific to E-cadherin, Slug,
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normalization control.
Plasmid constructs
Oligos designed to encompass hsa-miR-29 target site in
mRNA of NMI
5′–CTCTGAATCTTCTTTGTTTCAAATGGTGCTG
CATGTTTTCAACTAA –-3′ and 3′–AGCTTTAGTTG
AAAACATGCAGCACCATTTGAAACAAAGAAGATT
CAGAGAGCT—5′ were annealed and cloned into Hin-
dIII and SacI sites of the pMIR-Report vector (Ambion,
Austin, TX) to generate pMIR-REPORT29-NMI. For
expressing precursor miRNAs, we used HmiR0119-
MR04 for 29a or HmiR0120-MR04 for 29b and CmiR0001-
MR04 as miRNA scrambled control. For miRNA inhibition,
HmiR-AN0371-AM02 for 29a or HmiR-AN0373-AM02
for 29b were used. These precursor and miRNA inhibitor
plasmids were purchased from GeneCopoeia™ (Rockville,
MD, USA).
Luciferase assay
pMIR-REPORT29-NMI (with miR-29A or miR-29B pre-
cursors (Applied Biosystems) was transfected in MCF7
cells (70% confluent) using siPORT™NeoFX™ (Life Tech-
nologies) in serum free medium as per the manufac-
turer’s instructions. After incubation at 37°C in 5% CO2
for 36 hr, cells were lysed using Reporter Lysis Buffer as
per the manufacturer’s instructions (Promega, Madison,
WI). The luminescence was assessed using GloMax® 20/
20 luminometer (Promega). To block miR-29 expression,
cells were grown to 70% confluence and were trans-
fected using Lipofectamine 2000 (Life Technologies) in
serum free media with antagomirs for microRNA 29
(Exiqon, Woburn, MA, USA). After 48 hr protein was
isolated for analysis. For Wnt/β-catenin reporter assays,
transfections in T47D cells were done with 200 ng total
DNA (Top-Flash, M50) using Lipofectamine 2000.
Three-dimensional assay
3D cultures were grown following the protocol by
Debnath et al. [8,25,26]. Briefly, eight well-chambered
cover glass slides (Millipore, Billerica, MA) were
placed on ice and coated with 50 μl of 3D Culture
Matrix Basement Membrane Extract Reduced Growth
Factor (phenol red free) from Trevigen (Gaithersburg,
MD, USA). The slide was incubated for 30 min in 37°C
incubator. Cells (1000/well, 36 hr post transient trans-
fection of either precursor or antagonizing microRNA)
were plated in growth media containing 2% reduced
growth factor basement membrane extract (Trevigen,
Gaithersburg, MD). Media was changed every 4 days
and the morphology was documented digitally using a
Nikon Eclipse Ti-U microscope (Nikon, Tokyo, Japan)
using the 20 × objective.Immunocytochemistry
Cells were seeded at 100,000 cells per well in a 6 well
plate with 12 mm round poly-lysine coated glass cover-
slips. Cells were washed with PBS and then fixed for 30 mi-
nutes at room temperature in 4% paraformaldehyde.
Coverslips were then washed with PBS and blocked with
5% BSA in PBS with 0.3% Triton X-100 for 1hr. E-
cadherin antibody (Cell Signaling, Beverly, MA) was di-
luted 1:200 in 1% BSA in PBS with 0.3% Triton X-100 and
the coverslips were incubated overnight. Coverslips were
then incubated with anti-rabbit Alexa-Fluor 594 (Life
Technologies, Grand Island, New York); diluted 1:400 in
1%BSA in PBS with 0.3% Triton X-100. Coverslips were
washed with PBS and then were mounted onto glass slides
using VectaSheild with DAPI (Vector Labs, Burlingame,
CA). Images were captured using a Nikon Eclipse Ti-U.
Patient samples
After obtaining institutional review board approval (Ap-
proval #09-287; University of South Alabama), archived
patient samples were obtained according to established in-
stitutional policies. Informed consent was obtained from
all subjects. All specimens were coded and de-identified.
The specimens comprised primary breast tumors and
matched lymph node metastases obtained during surgical
procedures which were immediately stored in liquid nitro-
gen. Tissue specimens were homogenized and RNA was
extracted using QIAzol (Qiagen Inc., Valencia, CA). Ma-
ture microRNA levels were assessed using quantitative
real-time PCR (miScript SYBR-green PCR kit, Qiagen) fol-
lowing cDNA synthesis (miScript II RT kit, Qiagen).
Western blots
Cells were transfected with appropriate plasmid (or pre-
miRNA or antagomiRs as appropriate) using Lipofectamine
2000 according to manufacturer’s instructions (Life Tech-
nologies). Cells were harvested 42 hr post transfection in
NP-40 lysis buffer. The lysates (20 μg) were resolved on
SDS-PAGE and transferred onto PVDF membranes. Im-
munoblots were developed using relevant primary and sec-
ondary antibodies as per the respective manufacturer’s
instructions.
Invasion assay
Invasion assays were conducted using 8 μM polyethyl-
ene terpthalate filters (BioCoat™ Matrigel Invasion
Chambers, BD Pharmingen), as described earlier [27].
Cells (transfected with pre-miRs or antagomiRs as ap-
propriate) were allowed to invade through matrigel
coated filters for 16 hr. in a transwell. Cells invaded to
the lower sides of the transwell, cells were fixed using
4% (w/v) paraformaldehyde and were stained using
0.05% crystal violet, and the cell number was counted
as described before [28].
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McNemar test was used to determine the association be-
tween the expression of our gene of interest and the
microRNA expression. Other data was analyzed using
one-way Anova relative quantitation values were plotted
using GraphPad Prism (La Jolla, CA). The observations
were rendered statistically significant for P ≤ 0.05.
Results
miR-29 targets NMI
To identify candidate miRNAs that can potentially regu-
late NMI levels, we queried three publically available da-
tabases (Target Scan, microRNA.org and miRDB.org)
and cataloged miRNAs predicted to target the NMI tran-
script (3′ UTR) (Figure 1A). The outputs of these searches
were grouped to get the top hits, common to at least two
databases. Six miRNAs viz. miR-561, miR-664, miR-548
and miR-29 a, b, c were commonly present among the three
database searches. We investigated these miRNAs for their
known relevance to cancer biology. We did not notice any
significant cancer biology related publications for miR-561.
miR-664 has a potential tumor suppressive activity in hepa-
tocellular carcinoma and has been documented to down-
regulate methionine adenosyltransferase 1A (MAT1A) [29].
miR-548 is implied in regulating pancreatic cancer progres-
sion and downregulation of low-density lipoprotein
receptor-related protein (LRP1B), in thyroid cancer [30,31].
Our attention was specifically captured by miR-29 a, b, c be-
cause all the members of this family consistently ranked
high in the prediction algorithms of all three databases
searched. miR-29a is up-regulated and promotes self-
renewal in AML and increases EMT and metastasis in
breast cancer [32,33]. miR-29b is induced by c-Myc in
HMEC cells [34]. It is also upregulated in canine mammary
cancer and multiple gene expression analyses indicate its
upregulation in breast cancer [35-37]. miR-29a and c are
also upregulated in drug resistant breast cancer [38]. Thus,
based on our searches and compelling cues from published
findings, we focused our studies on testing the ability of the
miR-29 family in targeting NMI.
miR-29 a, b, c target identical sequences in the NMI 3′
UTR with a slight alteration in their binding capacity
based on variations outside the seed-sequence (Figure 1B).
To validate targeting of the NMI 3′UTR by miR-29, we
cloned the putative binding site of miR-29 in to the
pMIR-REPORT™ vector to generate pMIR-REPORT29-
NMI. This reporter was independently co-transfected
with miR-29 a, b or c. We observed approximately 50%
reduction in the activity of pMIR-REPORT29-NMI in
MCF7 cells (Figure 1C). We did not observe any sig-
nificant difference when activity of the miR-29 mem-
bers was compared with each other, implying that they
are capable of targeting NMI with comparable effi-
ciency. Due to these similar abilities of the miR-29family members, for this study we decided to focus on
miR-29 a and b.
NMI expression is reduced in aggressive mesenchymal
like cell lines [8]. We determined expression levels of
miR-29 a and b in select cell types of reported epithelial or
mesenchymal-like phenotype. MFC7, T47D and MDA-
MB-468 are epithelial like cells whereas MCF10CA.cl.a,
MCF10CA.cl.d, MDA-MB-231 are tumorigenic, highly in-
vasive (mesenchymal-like) and metastatic cell lines.
[MDA-MB-435 is considered as melanoma; however it is
included in this panel as it has low levels of NMI, more-
over NMI has been reported to reduce its invasive and
tumorigenic potential [8,9]]. We designated the observed
levels of miR-29 a and b from MCF7 cells as a reference
expression level in an epithelial-like cell line. We observed
(Figure 1D) that the mesenchymal cells have notably ele-
vated expression of miR-29 a and b compared to the
epithelial-like MCF7 or T47D cells, implying a possible in-
verse relationship of NMI and miR-29 expression.
To confirm the targeting of NMI by miR-29, we intro-
duced miR-29 a or b in MCF7 cells by transient transfec-
tion. We observed that both miRNAs were capable of
reducing the levels of NMI to a comparable extent. Con-
versely, inactivation of miR-29 would be expected to re-
instate NMI expression. In MDA-MB-231 cells, silencing
the expression of miR-29 a or b using respective anti-miRs
elevated the level of NMI protein (Figure 1E). These obser-
vations confirm that NMI is targeted by miR-29 a and b in
these cells.
miR-29 expression enhances invasive ability
We have previously reported that NMI acts as one of
the gatekeepers of the epithelial phenotype and our ob-
servations indicated that loss of NMI may be one of the
key events preceding EMT [8]. This suggests a possible
role of miR-29 in promoting invasion and EMT. To
evaluate the functional impact of miR-29 a and b on
EMT, we modulated (increased or decreased) expression
of miR-29 in breast cancer cells with mesenchymal or
epithelial-like phenotype and monitored their 3D growth
morphology. MCF7 and T47D cells are epithelial like and
form acinar structures in 3D growth matrix. Expression of
miR-29a or b in these cells perturbed their growth morph-
ology to grape-like or branched appearance. T47D cells
were more responsive to shape change driven by miR-29a
compared to miR-29b (Figure 2A). Conversely, when
highly invasive MDA-MB-231 cells were evaluated for
morphological changes after treatment with respective
anti-miRs for miR-29 a or b, their 3D growth morphology
lost its stellate appearance and acquired an irregular-
spherical shape indicative of a shift toward acinar-like
appearance. Similarly anti-miR treatments in MDA-
MB-435 resulted in a stark shift to spheroid-like struc-
tures (Figure 2B). Additionally, the positive impact of
Figure 1 miR-29 targets NMI. (A) Micro-RNAs predicted to target the NMI transcript are catalogued using three different data bases represented
as distinct columns. The top hits that were common to at least two data bases are represented. The highlighted miRNAs are common to all 3
searches. The miR-29 family is represented by underline. (B) Alignment of the miR-29 a, b, c seed sequence with the NMI 3′ UTR. Dashed lines
represent complementary base pairing. (C) pMIR-REPORT29-NMI (containing putative binding site of miR-29 from the 3′ UTR of NMI) was
co-transfected with pre-miR-29 or scrambled control. The assay was performed in triplicate and the experiment was performed twice. The luciferase
activity readings were normalized with activity from a co-transfected β-gal expressing control. The error bars represent standard error of the mean
(SEM). [*indicates p ≤0.05]. (D) Levels of each of the miR-29a and b mature transcripts from human breast cancer cell lines compared to MCF7, a
breast cancer cell line with distinct epithelial like characters using real time-quantitive-PCR. Reactions were performed in triplicate. The
corresponding level of NMI protein is seen in the adjacent western blot. GAPDH levels were used as loading control. (E) Transient transfection of MCF7
cells with pre-miR-29 a or b reduced NMI protein levels compared to scrambled control. On the other hand, MDA-MB-231 cells showed elevated levels of
NMI upon introduction of anti-miR-29 a or b.
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T47D transfected with miR-29 a and b showed notice-
able increase in invasion (T47D: 150-200% and MCF7:
120-140%). Conversely, silencing miR-29 a or b from
MDA-MB-435 cells dramatically reduced their invasive
ability. In MDA-MB-231, silencing miR-29a led to a sig-
nificant reduction in invasion whereas silencing miR-
29b in these cells did not show a statistically significant
effect (Figure 2C). Together, these observations indicate
ability of miR-29 to promote invasive ability of breast
cancer cells. However, it is interesting that the extent of
reduction in invasive phenotype of MDA-MB-231 is
much less striking than MDA-MB-435 though both areconsidered to be highly invasive. This suggests that
there are complex intrinsic molecular underpinnings
that decide invasive properties and these may vary for
each cell line. Thus their response to a single molecular
alteration may reveal only a partial picture.
We established T47D derived cell lines stably expressing
miR-29a and miR-29b. The growth morphology of the
miR-29 expressors looked noticeably different when ad-
herent growth on tissue culture plates was examined. Un-
like the scrambled control that retained the epithelial-like
cobble stone morphology with well-defined cell-to-cell
contacts, the miR-29 expressors showed an irregular fibro-
blastic appearance with cells that did not grow as tightly
Figure 2 miR-29a/b enhance mesenchymal phenotype. (A) Breast cancer cells with significant epithelial phenotype MCF7 and T47D were
treated with pre-miRNA HmiR0119-MR04 for 29a or HmiR0120-MR04 29b using transient transfection. The transfected cells were allowed to
recover and were analyzed for their 3D structure. Fluorescence allowed for tracking only the colonies which grew from transfected cells. The 3D
growth patterns were documented as photomicrographs using phase contrast microscopy. (B) Highly invasive breast cancer cells with noticeable
mesenchymal phenotype MDA-MB-231 and Melanoma cells with highly invasive and mesenchymal phenotypes MDA-MB-435 were treated with
anti-miRNA HmiR-AN0371-AM02 for 29a or HmiR-AN0373-AM02 for 29b using transient transfection. The transfected cells were allowed to recover and
were analyzed for their 3D structure. Fluorescence allowed for tracking only the colonies which grew from transfected cells. The 3D growth patterns
were documented as photomicrographs using phase contrast microscopy. (C) The same cells MCF7, T47D, MDA-MB-231 and MDA-MB-435 were
transected by respective miRNA or antagomiRs as stated before and analyzed for their invasion using a modified Boyden chamber assay. The assay was
performed for 16 hrs. Invaded cells were stained using crystal violet and enumerated. The results are represented as percent of control where the
control is expressed as 100%. Error bars represent ± SEM and *indicates P≤ 0.05
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jacent cells (Figure 3A and B). The 3D growth morph-
ology of these cells showed a grape like and protrusive
patterns unlike the control (Figure 3A). At the molecu-
lar level, these cells showed lack of E-cadherin staining
at the cell-cell junctions (Figure 3B). This loss was
noted at transcript levels as well as confirmed at the
protein level by western blot analysis (Figure 3D). Con-
comitant loss of keratin 18 was also observed support-
ing a shift to a more mesenchymal-like molecular
profile. Interestingly, a loss of KRT18 was not noticed at
the transcript level but we did notice a concomitant
gain of mesenchymal transcription factors SNAIL and
ZEB1 in T47D cells expressing miR-29 a and SLUG and
ZEB1 in miR-29b expressors. Thus, though the resultant
impacts of miR-29a or b on specific molecular indica-
tors of EMT are not identical, overall our observationsindicated a clear induction of a mesenchymal plasticity
following miR-29 expression.
miR-29 and NMI levels show inverse trends in breast
cancer tissues
To determine the relationship of miR-29 levels with NMI
expression in patient derived specimens, we analyzed total
RNA from a panel of fresh frozen 29 breast tumors (that
comprised primaries from patients with Stage III and IV
disease) and compared with matching surrounding (un-in-
volved) tissue by qRT-PCR for the levels of miR-29 a, b and
NMI. We observed a decrease in NMI expression in 24 out
of 29 specimens. miR-29 a or b or both were upregulated
in 17 of the total 29 (Figure 4A). McNemar’s test was used
to determine the association between the expression of
NMI and miR-29 a and b expression. Up-regulation of ei-
ther miR-29 a or b (or both) was considered a contributing
Figure 3 miR-29 expression promotes mesenchymal plasticity. (A) Growth morphologies of T47D cells stably expressing miR-29 a or b were
evaluated in tissue culture plates (2D growth) or in matrigel (3D growth). The results were documented as photomicrographs using phase
contrast microscopy. (B) T47D miR-29a and miR-29b cells show loss of E-cadherin staining at the membrane as compared to scrambled controls.
E- cadherin (red), DAPI (blue), and phase contrast images were taken at 20× (Scale bar =25 μm). (C) Quantitative real-time PCR of markers for
EMT, E-cadherin, Slug, Snail, or Zeb1 of T47D miR-29a or b expressing cells. Data are normalized to GAPDH expression and fold changes (log2) in
expression are relative to corresponding scrambled control. (D) Protein levels of epithelial markers, E-cadherin and Keratin 18 (KRT18) are reduced
by T47D miR-29a or b expression.
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Figure 4B a strong, inverse relationship between the
reduced expression of NMI and miR-29 expression was
observed (P < 0.0076). Furthermore, 14 of 17 patients
with high miR-29 expression showed low NMI expres-
sion and in three patients with high NMI expression
low expression of miR-29 was noted (p < 0.01). These
observations provide convincing in-vivo evidence of an
inverse relationship between NMI and miR-29.
Absence of NMI expression positively influences
miR-29 levels
Studies in human osteoblasts have indicated that Wnt
signaling positively regulates miR-29 expression [39,40].
We queried the ENCODE ChIP-Seq database and found
that the miR-29 a/b1 gene is a target of TCF transcrip-
tion factor(s) (Figure 5A) [41-43]. To test the impact ofWnt on miR-29 in breast cancer cells, we treated T47D
cells independently with Wnt3a or insulin and found a no-
ticeable increase in levels of miR-29 a and b (Figure 5B).
Insulin and Wnt actions result in eventual inactivation of
GSK3β status. Our previous findings had indicated that
overexpression of NMI can negatively impact Wnt/β-ca-
tenin signaling [9]. We analyzed activity of a Wnt/β-ca-
tenin reporter (TOP-FLASH) in T47D cells stably silenced
for NMI expression (T47D-shNMI) [8]. Compared to the
scrambled control, these cells showed higher baseline ac-
tivity of TOP-FLASH. Consistent with our expectation,
Wnt3a stimulus showed a robust activation of the reporter
in T47D-shNMI cells (Figure 5C). These findings indicate
that silencing NMI expression results in reduced con-
straints on canonical Wnt signaling. These cells also
showed significant elevation of miR-29 a and b (Figure 5D).
Both Wnt and insulin signaling pathways commonly
Figure 4 Inverse trend of expression for NMI and miR-29. (A) Total RNA from a panel of fresh frozen 29 invasive breast tumor specimens
with matching normal tissue was analyzed by qRT-PCR for the levels of miR-29 a, b and NMI. The values were normalized with individual
surrounding un-involved tissue. The results are expressed as level of transcript compared to individual un-involved tissue. (B) Association between the
expression of NMI and the microRNA expression was determined using McNemar’s test. High indicates positive value compared with respective
uninvolved tissue. Low indicates negative value compared to respective uninvolved tissue.
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GSK3β. NMI silenced cells show increased phospho-Ser-
9-GSK3β (Figure 5E). Phospho-Ser-9-GSK3β is an inactive
form of GSK3β that is incapable of restricting canonical
Wnt signaling. This inactivation may consequently result
in elevated miR-29 expression. Introduction of constitu-
tively active GSK3β (GSK3β-S9A) in T47D-shNMI re-
sulted in significant reduction of miR-29 expression
(Figure 5D). This indicates that inactivation of GSK3β due
to absence of NMI results in upregulation of miR-29 ex-
pression. Overall this data suggests that loss of NMI will
result in feed-forward activation of miR-29 expression.
Conclusion
Loss of NMI during breast cancer progression promotes
invasion and metastasis [8]. However, the reasons behind
this loss of expression were unclear. As summarized in
Figure 5F, our observations provide the first clue that
miR-29a and miR-29b are involved in negatively regulat-
ing the expression of NMI in breast cancer. Breast can-
cer lacks classical Wnt activating mutations (such as
APC) that are seen in colon cancer. However, aberrant
Wnt response in the form of nuclear β-catenin is fre-
quently observed in breast cancer [44-47]. In the tumor
microenvironment Wnt ligands are known to be present.
As well as alternative signaling that inactivates GSK3β
or suppressors of Wnt inhibitors (such as SFRPs, Dickkopf
proteins or Wif1) can aberrantly alter Wnt homeostasis to
an activated state [48]. Thus, the increased miR-29 levels
due to micro-environmental signals and/or as result of the
feed forward effect of reduced NMI will prompt additional
lowering of NMI levels and consequently result inunrestricted β-catenin signaling. The Wnt/β-catenin path-
way has a fundamental impact on tumor progression in-
cluding EMT and cancer stem cell phenotype. Thus
molecular alterations that contribute to the dysregula-
tion of Wnt homeostasis are critical to understanding
intricate details of the invasive progression of breast
cancer. miRNAs are mediators of the morphogen gra-
dient during development and thus the role of miRNAs
in EMT is anticipated [49].
Diverse roles have been attributed to miR-29. It has
been shown as a tumor suppressor due to its involve-
ment in promoting tumor cell apoptosis, by suppressing
DNA methylation of tumor-suppressor genes leading to
reduced proliferation and increased chemosensitivity
[50]. Additionally in cells with wild type P53, miR-29 ex-
pression supports stabilization of P53 [51]. However, its
role in EMT is debatable. Reports by Chou et al. imply
that loss of miR-29b is an EMT and metastasis promot-
ing event [52]. Contrary to that and consistent with our
observations, Gebeshuber et al. have shown that miR-
29a promotes EMT and metastatic ability by targeting
tristetraprolin [33]. Wang et al. have shown that miR-
29b expression promoted migration and invasion of hu-
man breast cancer cells possibly due to its ability to target
the tumor suppressor PTEN [53]. A notable observation
regarding the biologic role of miR-29 is that transgenic
miR-29 overexpressing mice spontaneously developed in-
dolent chronic lymphocytic leukemias [54]. The reasons
for these diverse roles of miR-29 could be many. Indi-
vidual miRNAs molecules target a wide range of
mRNAs. Thus, their role in cancer is highly context-
dependent. It depends on the expression status of their
Figure 5 Upregulation of miR-29 as a consequence of compromised NMI expression. (A) ChIP-data reported by the ENCODE project confirms the
existence of a TCF site in the upstream regulatory region of miR-29 a and b1 on chromosome 7. (B) T47D cells grown in growth factor free medium were
treated with Wnt3a ligand (100 ng/ml) or insulin (10 μg/ml) for 24 hr. Levels of miR-29 a/b using RT-PCR. The levels were compared to untreated cells
(control), set arbitrarily at 100%. (C) T47D-shNMI cells (stably silenced for NMI) were evaluated for β-catenin driven transcription activity (using TOP-FLASH
reporter) at basal levels or with Wnt3a (100 ng/ml) treatment. This activity was compared to the T47D-scrambled control cells. Error bars represent ± SEM
and *indicates P ≤ 0.05. (D) Total RNA from T47D-shNMI cells was analyzed for levels of miR-29a and b and compared with T47D-scrambled control cells.
Introduction of constitutively active GSK3β (CA-GSK3β) in T47D-shNMI resulted in significant reduction of miR-29 expression. Error bars represent ± SEM
and *indicates P ≤ 0.05. (E) Total protein from T47D-shNMI and corresponding scrambled control cells was analyzed for the levels of total GSK3β and
phospho-Ser-9-GSK3β using western blot analysis. Level of NMI confirmed the stable silencing of NMI in these cells and GAPDH was used as a loading
control. (F) Proposed model of miR-29 signaling: In absence of NMI and/or due to micro-environmental signals such as Wnt or insulin, GSK3β is
inactivated (upon phosphorylation at Ser 9). That leads to increased miR-29 levels possibly by elimination of check on TCF driven transcription. miR-29
in turn targets NMI, which is one of the factors responsible to guard the active status of GSK3β; thus driving a feed forward loop for miR-29 activation
and sustained loss of NMI. This signaling mechanism may be one of the promoters of invasive progression of breast cancer.
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itionally, within a cell type, there may be temporal dif-
ferences that may be dictated by cell physiology and
impact of tumor microenvironment. MiR-29a and miR-
29b1 are transcribed from a locus on chromosome 7
while the miR-29b2 and miR-29c locus is on chromo-
some 1. Based on their promoter sequence, both loci
have distinct regulatory elements. The existence of such
complex distinct regulation for the miR-29 family mem-
bers is a compelling indicator of context-dependentregulation of these miRNAs. Consequently diverse im-
pacts on their target genes and resultant diverse pheno-
typic manifestations are conceivable. Our analysis of RNA
from tumors specimens corresponding to patients with in-
vasive and metastatic stage breast cancer shows an inverse
relationship miR-29 and NMI and thus underscores the
disease relevance of our findings. Cumulatively, we con-
clude that miR-29 family has a critical role in mediating
loss of NMI and subsequent EMT in breast cancer
progression.
Rostas et al. Molecular Cancer 2014, 13:200 Page 10 of 11
http://www.molecular-cancer.com/content/13/1/200Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conception and design: JWR, HCP, LAS, RSS. Development of Methodology:
JWR, HCP, AM, BM, SKB, SB, DJD, DLD, WOR, JAT. Acquisition of data: JWR,
HCP, AM, BM, SKB, DJD, Analysis and interpretation of data: (statistical analysis,
Computational analysis): SB, KS, RS, JWR, DJD, HCP. Writing, review, and/or
revision of the manuscript: JWR, HCP. SB,LS, RS, Administrative, technical, or
material support (organizing data, constructing databases, specimen
collection etc.): LS, DLD, WOR, JAT, JWR, RSS. Study supervision: RSS.
All authors read and approved the final version of manuscript.
Acknowledgements
Grant support: USPHS grants CA140472 (RSS) and CA138850 (LAS).
J. Rostas is a recipient of the American Medical Association Seed Grant 2011.
Drs. S. Bae and K.P. Singh’s work was partially supported by the Center grant of
the National Cancer Institute of the National Institutes of Health to the University
of Alabama at Birmingham Comprehensive Cancer Center (P30 CA013148)
H. Pruitt is a HHMI-Med-To-Grad Fellow (UAB).
Daniel J. Devine: Current Address: St. Jude Children’s Research Hospital,
Department of Oncology, 262 Danny Thomas Blvd. Memphis, TN 38105.
Author details
1Department of Pathology, University of Alabama at Birmingham, WTI-320E,
1824 6th avenue South, Birmingham, AL 35294, USA. 2Department of
Surgery, University of South Alabama, Mobile, AL, USA. 3Mitchell Cancer
Institute, University of South Alabama, Mobile, AL, USA.
4BBSF-Comprehensive Cancer Center, University of Alabama at Birmingham,
Birmingham, AL, USA. 5Department of Pathology, University of South
Alabama, Mobile, AL, USA. 6Comprehensive Cancer Center, University of
Alabama at Birmingham, Birmingham, AL, USA.
Received: 30 April 2014 Accepted: 21 August 2014
Published: 29 August 2014
References
1. Bao J, Zervos AS: Isolation and characterization of Nmi, a novel partner of
Myc proteins. Oncogene 1996, 12:2171–2176.
2. Bannasch D, Weis I, Schwab M: Nmi protein interacts with regions that
differ between MycN and Myc and is localized in the cytplasm of
neuroblastoma cells in contrast to nuclear MycN. Oncogene 1999,
18:6810–6817.
3. Zhu M, Susan J, Maria B, Leonard WJ: Functional Association of Nmi with
Stat5 and Stat1 in IL-2- and IFNγ-mediated signaling. Cell 1999,
96:121–130.
4. Li H, Tae-Hee L, Hava A: A novel tricomplex of BRCA1, Nmi, and c-Myc
Inhibits c-Myc-induced human telomerase reverse transcriptase gene
(hTERT) promoter activity in breast cancer. J Biol Chem 2002,
277:20965–20973. doi:10.1074/jbc.M112231200.
5. Schlierf B, Lang S, Kosian T, Werner T, Wegner M: The high-mobility group
transcription factor Sox10 interacts with the N-myc-interacting protein
Nmi. J Mol Biol 2005, 353:1033–1042. doi:10.1016/j.jmb.2005.09.013.
6. Zhang K, Zheng G, Yang Y: Stability of Nmi protein is controlled by its
association with Tip60. Mol Cell Biol 2007, 303:1–8. doi:10.1007/s11010-007-
9449-y.
7. Li Z, Hou J, Sun L, Wen T, Wang L, Zhao X, Xie Q, Zhang SQ: NMI mediates
transcription-independent ARF regulation in response to cellular stresses.
Mol Biol Cell 2012, 23:4635–4646. doi:10.1091/mbc.E12-04-0304.
8. Devine DJ, Rostas JW, Metge BJ, Das S, Mulekar MS, Tucker JA, Grizzle WE,
Buchsbaum DJ, Shevde LA, Samant RS: Loss of N-Myc interactor promotes
epithelial-mesenchymal transition by activation of TGF-beta/SMAD
signaling. Oncogene 2013, doi:10.1038/onc.2013.215.
9. Fillmore RA, Mitra A, Xi Y, Ju J, Scammell J, Shevde LA, Samant RS: Nmi
(N-Myc interactor) inhibits Wnt/β-catenin signaling and retards tumor
growth. Int J Cancer 2009, 125:556–564.
10. Lovat F, Valeri N, Croce CM: MicroRNAs in the pathogenesis of cancer.
Semin Oncol 2011, 38:724–733. doi:10.1053/j.seminoncol.2011.08.006.
11. Sharma S, Kelly TK, Jones PA: Epigenetics in cancer. Carcinogenesis 2010,
31:27–36. doi:10.1093/carcin/bgp220.12. Huynh KT, Hoon DS: Epigenetics of regional lymph node metastasis in
solid tumors. Clin Exp Metastas 2012, 29:747–756. doi:10.1007/s10585-012-
9491-3.
13. Fabian MR, Sundermeier TR, Sonenberg N: Understanding how miRNAs
post-transcriptionally regulate gene expression. Prog Mol Subcell Biol
2010, 50:1–20. doi:10.1007/978-3-642-03103-8_1.
14. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 2004, 116:281–297.
15. Yu Z, Pestell RG: Small non-coding RNAs govern mammary gland
tumorigenesis. J Mammary Gland Biol Neoplasia 2012, 17:59–64.
doi:10.1007/s10911-012-9246-4.
16. Piao HL, Ma L: Non-coding RNAs as regulators of mammary development
and breast cancer. J Mammary Gland Biol Neoplasia 2012, 17:33–42.
doi:10.1007/s10911-012-9245-5.
17. Valastyan S: Roles of microRNAs and other non-coding RNAs in breast
cancer metastasis. J Mammary Gland Biol Neoplasia 2012, 17:23–32.
doi:10.1007/s10911-012-9241-9.
18. Lewis BP BC, Bartel DP; 2005. http://www.targetscan.org/.
19. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA
targets. Cell 2005, 120:15–20. doi:10.1016/j.cell.2004.12.035.
20. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS: Human
MicroRNA targets. PLoS Biol 2005, 3(7):e264. doi:10.1371/journal.
pbio.0020363.
21. John B, Sander C, Marks DS: Prediction of human microRNA targets.
Methods Mol Biol 2006, 342:101–113. doi:10.1385/1-59745-123-1:101.
22. Xiaowei Wang’s lab at the Department of Radiation Oncology, W. U. S. o. M.
i. S. L; 2012. http://mirdb.org/miRDB/.
23. Wang X: miRDB: a microRNA target prediction and functional annotation
database with a wiki interface. RNA 2008, 14:1012–1017.
doi:10.1261/rna.965408.
24. Wang X, El Naqa IM: Prediction of both conserved and nonconserved
microRNA targets in animals. Bioinformatics 2008, 24:325–332.
doi:10.1093/bioinformatics/btm595.
25. Debnath J, Muthuswamy SK, Brugge JS: Morphogenesis and oncogenesis
of MCF-10A mammary epithelial acini grown in three-dimensional
basement membrane cultures. Methods 2003, 30:256–268.
26. Debnath J, Brugge JS: Modelling glandular epithelial cancers in
three-dimensional cultures. Nat Rev Cancer 2005, 5:675–688. doi:10.1038/nrc1695.
27. Menezes ME, Mitra A, Shevde LA, Samant RS: DNAJB6 governs a novel
regulatory loop determining Wnt/beta-catenin signalling activity.
Biochem J 2012, 444:573–580. doi:10.1042/BJ20120205.
28. Mitra A, Fillmore RA, Metge BJ, Rajesh M, Xi Y, King J, Ju J, Pannell L, Shevde
LA, Samant RS: Large isoform of MRJ (DNAJB6) reduces malignant activity
of breast cancer. Breast Cancer Res 2008, 10:R22. doi:10.1186/bcr1874.
29. Yang H, Cho ME, Li TW, Peng H, Ko KS, Mato JM, Lu SC: MicroRNAs
regulate methionine adenosyltransferase 1A expression in hepatocellular
carcinoma. J Clin Investig 2013, 123:285–298. doi:10.1172/JCI63861.
30. Prazeres H, Torres J, Rodrigues F, Pinto M, Pastoriza MC, Gomes D,
Cameselle-Teijeiro J, Vidal A, Martins TC, Sobrinho-Simoes M, Soares P:
Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B,
a modulator of the extracellular environment of thyroid cancer cells.
Oncogene 2011, 30:1302–1317. doi:10.1038/onc.2010.512.
31. Heyn H, Schreek S, Buurman R, Focken T, Schlegelberger B, Beger C:
MicroRNA miR-548d is a superior regulator in pancreatic cancer.
Pancreas 2012, 41:218–221. doi:10.1097/MPA.0b013e318224b701.
32. Han YC, Park CY, Bhagat G, Zhang J, Wang Y, Fan JB, Liu M, Zou Y,
Weissman IL, Gu H: microRNA-29a induces aberrant self-renewal capacity
in hematopoietic progenitors, biased myeloid development, and acute
myeloid leukemia. J Exp Med 2010, 207:475–489. doi:10.1084/jem.20090831.
33. Gebeshuber CA, Zatloukal K, Martinez J: miR-29a suppresses tristetraprolin,
which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009,
10:400–405. doi:10.1038/embor.2009.9.
34. Kim JW, Mori S, Nevins JR: Myc-induced microRNAs integrate
Myc-mediated cell proliferation and cell fate. Cancer Res 2010,
70:4820–4828. doi:10.1158/0008-5472.CAN-10-0659.
35. Boggs RM, Wright ZM, Stickney MJ, Porter WW, Murphy KE: MicroRNA
expression in canine mammary cancer. Mamm Genome 2008, 19:561–569.
doi:10.1007/s00335-008-9128-7.
36. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E,
Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A,
Rostas et al. Molecular Cancer 2014, 13:200 Page 11 of 11
http://www.molecular-cancer.com/content/13/1/200Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM:
MicroRNA gene expression deregulation in human breast cancer.
Cancer Res 2005, 65:7065–7070. doi:10.1158/0008-5472.CAN-05-1783.
37. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V,
Ginzinger D, Getts R, Haqq C: Optimized high-throughput microRNA
expression profiling provides novel biomarker assessment of clinical
prostate and breast cancer biopsies. Mol Cancer 2006, 5:24.
doi:10.1186/1476-4598-5-24.
38. Chen GQ, Zhao ZW, Zhou HY, Liu YJ, Yang HJ: Systematic analysis of
microRNA involved in resistance of the MCF-7 human breast cancer cell to
doxorubicin. Med Oncol 2010, 27:406–415. doi:10.1007/s12032-009-9225-9.
39. Kapinas K, Kessler C, Ricks T, Gronowicz G, Delany AM: miR-29 modulates
Wnt signaling in human osteoblasts through a positive feedback loop.
J Biol Chem 2010, 285:25221–25231. doi:10.1074/jbc.M110.116137.
40. Kapinas K, Kessler CB, Delany AM: miR-29 suppression of osteonectin in
osteoblasts: regulation during differentiation and by canonical Wnt
signaling. J Cell Biochem 2009, 108:216–224. doi:10.1002/jcb.22243.
41. Lee CC, Chen WS, Chen CC, Chen LL, Lin YS, Fan CS, Huang TS: TCF12
protein functions as transcriptional repressor of E-cadherin, and its
overexpression is correlated with metastasis of colorectal cancer. J Biol
Chem 2012, 287:2798–2809. doi:10.1074/jbc.M111.258947.
42. Consortium EP: A user’s guide to the encyclopedia of DNA elements
(ENCODE). PLoS Biol 2011, 9:e1001046. doi:10.1371/journal.pbio.1001046.
43. Rosenbloom KR, Sloan CA, Malladi VS, Dreszer TR, Learned K, Kirkup VM,
Wong MC, Maddren M, Fang R, Heitner SG, Lee BT, Barber GP, Harte RA,
Diekhans M, Long JC, Wilder SP, Zweig AS, Karolchik D, Kuhn RM, Haussler
D, Kent WJ: ENCODE data in the UCSC Genome Browser: year 5 update.
Nucleic Acids Res 2013, 41:D56–63. doi:10.1093/nar/gks1172.
44. Li S, Sun Y, Li L: The expression of beta-catenin in different subtypes of
breast cancer and its clinical significance. Tumour Biol 2014, doi:10.1007/
s13277-014-1975-0.
45. Dey N, Young B, Abramovitz M, Bouzyk M, Barwick B, De P, Leyland-Jones B:
Differential activation of Wnt-beta-catenin pathway in triple negative
breast cancer increases MMP7 in a PTEN dependent manner. PLoS ONE
2013, 8:e77425. doi:10.1371/journal.pone.0077425.
46. Incassati A, Chandramouli A, Eelkema R, Cowin P: Key signaling nodes in
mammary gland development and cancer: beta-catenin. Breast Cancer
Res 2010, 12:213. doi:10.1186/bcr2723.
47. Mukherjee N, Bhattacharya N, Alam N, Roy A, Roychoudhury S, Panda CK:
Subtype-specific alterations of the Wnt signaling pathway in breast
cancer: clinical and prognostic significance. Cancer Sci 2012,
103:210–220. doi:10.1111/j.1349-7006.2011.02131.x.
48. Menezes ME, Devine DJ, Shevde LA, Samant RS: Dickkopf1: a tumor
suppressor or metastasis promoter? Int J Cancer 2012, 130:1477–1483.
doi:10.1002/ijc.26449.
49. Inui M, Montagner M, Piccolo S: miRNAs and morphogen gradients.
Curr Opin Cell Biol 2012, 24:194–201. doi:10.1016/j.ceb.2011.11.013.
50. Jiang H, Zhang G, Wu JH, Jiang CP: Diverse roles of miR-29 in cancer
(Review). Oncol Rep 2014, doi:10.3892/or.2014.3036.
51. Park SY, Lee JH, Ha M, Nam JW, Kim VN: miR-29 miRNAs activate p53 by
targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009, 16:23–29.
doi:10.1038/nsmb.1533.
52. Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z: GATA3 suppresses
metastasis and modulates the tumour microenvironment by regulating
microRNA-29b expression. Nat Cell Biol 2013, 15:201–213. doi:10.1038/ncb2672.
53. Wang C, Bian Z, Wei D, Zhang JG: miR-29b regulates migration of human
breast cancer cells. Mol Cell Biochem 2011, 352:197–207. doi:10.1007/
s11010-011-0755-z.
54. Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, Volinia
S, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y: Chronic lymphocytic
leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad
Sci U S A 2010, 107:12210–12215. doi:10.1073/pnas.1007186107.
doi:10.1186/1476-4598-13-200
Cite this article as: Rostas et al.: microRNA-29 negatively regulates EMT
regulator N-myc interactor in breast cancer. Molecular Cancer 2014 13:200.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
